EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase III)Open Access · CC BY-NC 4.0

Long-term safety, efficacy and functional outcomes of atogepant for the preventive treatment of migraine

Sait Ashina iD, Messoud Ashina iD, Dagny Holle-Lee, Cristina Tassorelli iD, Soo-Jin Cho iD, Molly Yizeng He, Rosa De Abreu Ferreira, Pranav Gandhi iD, Jonathan H Smith, Kimberly Pfleeger, Joel M Trugman

Cephalalgia · 2025-08 · 45 (8)

DOI: 10.1177/03331024251365206 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cephalalgia, online erschienen am 19.08.2025. Verfasst von Sait Ashina und 10 weiteren Autor:innen. Beteiligte Einrichtung: BIDMC Comprehensive Headache Center, Beth Israel Deaconess Medical Center, Boston, MA, USA. Hauptthemen laut MEDLINE: Migraine Disorders, Calcitonin Gene-Related Peptide Receptor Antagonists. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Long-term data for oral calcitonin gene-related peptide receptor antagonist, atogepant, in episodic migraine (EM) has been reported. This is the first report on one-year outcomes in participants with chronic migraine (CM) and in the EM population with prior preventive treatment failures. Here, we report the long-term safety, tolerability, efficacy and functional outcomes of one-year preventive treatment of EM or CM with atogepant.

Methods

This is an interim analysis of an ongoing, open-label, multicenter, 156-week, safety extension study that enrolled completers from phase 3 PROGRESS and ELEVATE trials. The participants completing week 52 or early termination were evaluated. Eligible adults with at least a one-year history of migraine, with either CM (PROGRESS) or EM who previously had inadequate response to two to four classes of conventional oral preventive treatments (ELEVATE). All participants received atogepant 60 mg once daily. The primary outcome was safety and tolerability of atogepant. Efficacy and functional outcomes were prespecified exploratory analyses.

Results

Of 596 participants, 595 (PROGRESS, n = 325; ELEVATE, n = 270) were treated and included in the safety population and 524 (PROGRESS, n = 284; ELEVATE, n = 240) were included in the modified intent-to-treat population. In this interim analysis, mean duration of atogepant exposure was 496.5 days. Treatment-emergent adverse events (TEAEs) occurred in 79.0% of participants; most were mild/moderate and not related to atogepant. Common TEAEs (≥5%) included COVID-19 (28.7%), nasopharyngitis (10.9%) and constipation (8.2%). TEAEs leading to discontinuation occurred in 5.9% of participants. One death attributed to asphyxia by housefire was observed. Other serious TEAEs occurred in 5.5% of participants and none were related to atogepant. Alanine aminotransferase and/or aspartate aminotransferase ≥3× upper limit of normal occurred in two participants; neither met Hy's law criteria. Improvements in efficacy and functional outcomes from lead-in study baseline were observed at weeks 13–16 in this open-label study and were consistent through 48 and 52 weeks, respectively.

Conclusions

Overall safety results were consistent with the known safety profile of atogepant and the drug was well-tolerated over the course of the study. No new safety signals were identified. Improvements in efficacy and functional outcomes were consistent during the study. Trial Registration ClinicalTrials.gov identifier: NCT04686136.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersCalcitonin Gene-Related Peptide Receptor AntagonistsHumansMaleFemaleAdultMiddle AgedTreatment OutcomeYoung AdultAged

Stichwörter der Autor:innen

atogepantclinical trialheadacheinterim analysismigraine days

Substanzen

Calcitonin Gene-Related Peptide Receptor Antagonists

Autor:innen und Institutionen

  • BIDMC Comprehensive Headache Center, Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • Department of Neurology and Department of Anesthesia, Critical Care and Pain Medicine, Harvard Medical School, Boston, MA, USA.
  • Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
  • Department of Neurology, Danish Headache Center, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
  • Department of Neurology, West German Headache and Vertigo Center Essen, University of Essen, Essen, Germany.
  • Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.

ORCID-Profile: Sait Ashina, Messoud Ashina, Cristina Tassorelli, Soo-Jin Cho, Pranav Gandhi

Förderung

  • AbbVie

Zitieren

APA

Ashina, S., Ashina, M., Holle-Lee, D., Tassorelli, C., Cho, S. J., He, M. Y., De Abreu Ferreira, R., Gandhi, P., Smith, J. H., Pfleeger, K., & Trugman, J. M. (2025). Long-term safety, efficacy and functional outcomes of atogepant for the preventive treatment of migraine. Cephalalgia, 45(8). https://doi.org/10.1177/03331024251365206

Vancouver

Ashina S, Ashina M, Holle-Lee D, Tassorelli C, Cho SJ, He MY, et al. Long-term safety, efficacy and functional outcomes of atogepant for the preventive treatment of migraine. Cephalalgia. 2025;45(8). doi:10.1177/03331024251365206

BibTeX
@article{Ashina2025,
  author = {Ashina, Sait and Ashina, Messoud and Holle-Lee, Dagny and Tassorelli, Cristina and Cho, Soo-Jin and He, Molly Yizeng and De Abreu Ferreira, Rosa and Gandhi, Pranav and Smith, Jonathan H and Pfleeger, Kimberly and Trugman, Joel M},
  title = {Long-term safety, efficacy and functional outcomes of atogepant for the preventive treatment of migraine},
  journal = {Cephalalgia},
  year = {2025},
  volume = {45},
  number = {8},
  doi = {10.1177/03331024251365206}
}
Kostenlos starten →